BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Abikhair Burgo M, Roudiani N, Chen J, Santana AL, Doudican N, Proby C, Felsen D, Carucci JA. Ruxolitinib inhibits cyclosporine-induced proliferation of cutaneous squamous cell carcinoma. JCI Insight 2018;3:120750. [PMID: 30185657 DOI: 10.1172/jci.insight.120750] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Corchado-Cobos R, García-Sancha N, González-Sarmiento R, Pérez-Losada J, Cañueto J. Cutaneous Squamous Cell Carcinoma: From Biology to Therapy. Int J Mol Sci 2020;21:E2956. [PMID: 32331425 DOI: 10.3390/ijms21082956] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 9.0] [Reference Citation Analysis]
2 Pan Y, Du D, Wang L, Wang X, He G, Jiang X. The Role of T Helper 22 Cells in Dermatological Disorders. Front Immunol 2022;13:911546. [DOI: 10.3389/fimmu.2022.911546] [Reference Citation Analysis]
3 Vastarella M, Fabbrocini G, Sibaud V. Hyperkeratotic Skin Adverse Events Induced by Anticancer Treatments: A Comprehensive Review. Drug Saf 2020;43:395-408. [PMID: 31981081 DOI: 10.1007/s40264-020-00907-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
4 Yao Y, Yang G, Lu G, Ye J, Cui L, Zeng Z, Chen J, Zhou J, Duan L. Th22 Cells/IL-22 Serves as a Protumor Regulator to Drive Poor Prognosis through the JAK-STAT3/MAPK/AKT Signaling Pathway in Non-Small-Cell Lung Cancer. Journal of Immunology Research 2022;2022:1-12. [DOI: 10.1155/2022/8071234] [Reference Citation Analysis]
5 Thai AA, Lim AM, Solomon BJ, Rischin D. Biology and Treatment Advances in Cutaneous Squamous Cell Carcinoma. Cancers (Basel) 2021;13:5645. [PMID: 34830796 DOI: 10.3390/cancers13225645] [Reference Citation Analysis]
6 Liu X, Michael S, Bharti K, Ferrer M, Song MJ. A biofabricated vascularized skin model of atopic dermatitis for preclinical studies. Biofabrication 2020;12:035002. [PMID: 32059197 DOI: 10.1088/1758-5090/ab76a1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 8.5] [Reference Citation Analysis]
7 Blue ED, Freeman SC, Lobl MB, Clarey DD, Fredrick RL, Wysong A, Whitley MJ. Cutaneous squamous cell carcinoma arising in immunosuppressed patients: a systematic review of tumor profiling studies. JID Innovations 2022. [DOI: 10.1016/j.xjidi.2022.100126] [Reference Citation Analysis]
8 Ansary TM, Hossain MR, Komine M, Ohtsuki M. Immunotherapy for the Treatment of Squamous Cell Carcinoma: Potential Benefits and Challenges. IJMS 2022;23:8530. [DOI: 10.3390/ijms23158530] [Reference Citation Analysis]
9 Tegtmeyer K, Ravi M, Zhao J, Maloney NJ, Lio PA. Off-label Studies on the Use of Ruxolitinib in Dermatology. Dermatitis 2021;32:164-72. [PMID: 33443378 DOI: 10.1097/DER.0000000000000658] [Reference Citation Analysis]
10 Gambichler T, Stockfleth E, Susok L. Aggressive cutaneous squamous cell carcinoma in a hydroxyurea- and ruxolitinib-pretreated patient with polycythaemia vera. J Eur Acad Dermatol Venereol 2022;36 Suppl 1:63-5. [PMID: 34855240 DOI: 10.1111/jdv.17406] [Reference Citation Analysis]
11 Hassan S, Purdie KJ, Wang J, Harwood CA, Proby CM, Pourreyron C, Mladkova N, Nagano A, Dhayade S, Athineos D, Caley M, Mannella V, Blyth K, Inman GJ, Leigh IM. A Unique Panel of Patient-Derived Cutaneous Squamous Cell Carcinoma Cell Lines Provides a Preclinical Pathway for Therapeutic Testing. Int J Mol Sci 2019;20:E3428. [PMID: 31336867 DOI: 10.3390/ijms20143428] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
12 Stevenson ML, Carucci J, Colegio OR. Skin cancer in transplant recipients: Scientific retreat of the international immunosuppression and transplant skin cancer collaborative and skin care in organ transplant patients—Europe. Clin Transplant 2019;33. [DOI: 10.1111/ctr.13736] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]